Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. / Morze, Jakub; Wittenbecher, Clemens; Schwingshackl, Lukas; Danielewicz, Anna; Rynkiewicz, Andrzej; Hu, Frank B.; Guasch-Ferré, Marta.

In: Diabetes Care, 2022, p. 1013–1024.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Morze, J, Wittenbecher, C, Schwingshackl, L, Danielewicz, A, Rynkiewicz, A, Hu, FB & Guasch-Ferré, M 2022, 'Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies', Diabetes Care, pp. 1013–1024. https://doi.org/10.2337/dc21-1705

APA

Morze, J., Wittenbecher, C., Schwingshackl, L., Danielewicz, A., Rynkiewicz, A., Hu, F. B., & Guasch-Ferré, M. (2022). Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. Diabetes Care, 1013–1024. https://doi.org/10.2337/dc21-1705

Vancouver

Morze J, Wittenbecher C, Schwingshackl L, Danielewicz A, Rynkiewicz A, Hu FB et al. Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. Diabetes Care. 2022;1013–1024. https://doi.org/10.2337/dc21-1705

Author

Morze, Jakub ; Wittenbecher, Clemens ; Schwingshackl, Lukas ; Danielewicz, Anna ; Rynkiewicz, Andrzej ; Hu, Frank B. ; Guasch-Ferré, Marta. / Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies. In: Diabetes Care. 2022 ; pp. 1013–1024.

Bibtex

@article{0d98ca5021c84041b38931fc6a690b95,
title = "Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies",
abstract = "BACKGROUNDDue to the rapidly increasing availability of metabolomics data in prospective studies, an update of the meta evidence on metabolomics and type 2 diabetes risk is warranted.PURPOSETo conduct an updated systematic review and meta-analysis of plasma, serum, and urine metabolite markers and incident type 2 diabetes.DATA SOURCESWe searched PubMed and Embase until 6 March 2021.STUDY SELECTIONWe selected prospective observational studies where investigators used high-throughput techniques to investigate the relationship between plasma, serum, or urine metabolites and incident type 2 diabetes.DATA EXTRACTIONBaseline metabolites per-SD risk estimates and 95% CIs for incident type 2 diabetes were extracted from all eligible studies.DATA SYNTHESISA total of 61 reports with 71,196 participants and 11,771 type 2 diabetes cases/events were included in the updated review. Meta-analysis was performed for 412 metabolites, of which 123 were statistically significantly associated (false discovery rate–corrected P < 0.05) with type 2 diabetes risk. Higher plasma and serum levels of certain amino acids (branched-chain, aromatic, alanine, glutamate, lysine, and methionine), carbohydrates and energy-related metabolites (mannose, trehalose, and pyruvate), acylcarnitines (C4-DC, C4-OH, C5, C5-OH, and C8:1), the majority of glycerolipids (di- and triacylglycerols), (lyso)phosphatidylethanolamines, and ceramides included in meta-analysis were associated with higher risk of type 2 diabetes (hazard ratio 1.07–2.58). Higher levels of glycine, glutamine, betaine, indolepropionate, and (lyso)phosphatidylcholines were associated with lower type 2 diabetes risk (hazard ratio 0.69–0.90).LIMITATIONSSubstantial heterogeneity (I2 > 50%, τ2 > 0.1) was observed for some of the metabolites.CONCLUSIONSSeveral plasma and serum metabolites, including amino acids, lipids, and carbohydrates, are associated with type 2 diabetes risk.",
author = "Jakub Morze and Clemens Wittenbecher and Lukas Schwingshackl and Anna Danielewicz and Andrzej Rynkiewicz and Hu, {Frank B.} and Marta Guasch-Ferr{\'e}",
year = "2022",
doi = "10.2337/dc21-1705",
language = "English",
pages = "1013–1024",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association",

}

RIS

TY - JOUR

T1 - Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies

AU - Morze, Jakub

AU - Wittenbecher, Clemens

AU - Schwingshackl, Lukas

AU - Danielewicz, Anna

AU - Rynkiewicz, Andrzej

AU - Hu, Frank B.

AU - Guasch-Ferré, Marta

PY - 2022

Y1 - 2022

N2 - BACKGROUNDDue to the rapidly increasing availability of metabolomics data in prospective studies, an update of the meta evidence on metabolomics and type 2 diabetes risk is warranted.PURPOSETo conduct an updated systematic review and meta-analysis of plasma, serum, and urine metabolite markers and incident type 2 diabetes.DATA SOURCESWe searched PubMed and Embase until 6 March 2021.STUDY SELECTIONWe selected prospective observational studies where investigators used high-throughput techniques to investigate the relationship between plasma, serum, or urine metabolites and incident type 2 diabetes.DATA EXTRACTIONBaseline metabolites per-SD risk estimates and 95% CIs for incident type 2 diabetes were extracted from all eligible studies.DATA SYNTHESISA total of 61 reports with 71,196 participants and 11,771 type 2 diabetes cases/events were included in the updated review. Meta-analysis was performed for 412 metabolites, of which 123 were statistically significantly associated (false discovery rate–corrected P < 0.05) with type 2 diabetes risk. Higher plasma and serum levels of certain amino acids (branched-chain, aromatic, alanine, glutamate, lysine, and methionine), carbohydrates and energy-related metabolites (mannose, trehalose, and pyruvate), acylcarnitines (C4-DC, C4-OH, C5, C5-OH, and C8:1), the majority of glycerolipids (di- and triacylglycerols), (lyso)phosphatidylethanolamines, and ceramides included in meta-analysis were associated with higher risk of type 2 diabetes (hazard ratio 1.07–2.58). Higher levels of glycine, glutamine, betaine, indolepropionate, and (lyso)phosphatidylcholines were associated with lower type 2 diabetes risk (hazard ratio 0.69–0.90).LIMITATIONSSubstantial heterogeneity (I2 > 50%, τ2 > 0.1) was observed for some of the metabolites.CONCLUSIONSSeveral plasma and serum metabolites, including amino acids, lipids, and carbohydrates, are associated with type 2 diabetes risk.

AB - BACKGROUNDDue to the rapidly increasing availability of metabolomics data in prospective studies, an update of the meta evidence on metabolomics and type 2 diabetes risk is warranted.PURPOSETo conduct an updated systematic review and meta-analysis of plasma, serum, and urine metabolite markers and incident type 2 diabetes.DATA SOURCESWe searched PubMed and Embase until 6 March 2021.STUDY SELECTIONWe selected prospective observational studies where investigators used high-throughput techniques to investigate the relationship between plasma, serum, or urine metabolites and incident type 2 diabetes.DATA EXTRACTIONBaseline metabolites per-SD risk estimates and 95% CIs for incident type 2 diabetes were extracted from all eligible studies.DATA SYNTHESISA total of 61 reports with 71,196 participants and 11,771 type 2 diabetes cases/events were included in the updated review. Meta-analysis was performed for 412 metabolites, of which 123 were statistically significantly associated (false discovery rate–corrected P < 0.05) with type 2 diabetes risk. Higher plasma and serum levels of certain amino acids (branched-chain, aromatic, alanine, glutamate, lysine, and methionine), carbohydrates and energy-related metabolites (mannose, trehalose, and pyruvate), acylcarnitines (C4-DC, C4-OH, C5, C5-OH, and C8:1), the majority of glycerolipids (di- and triacylglycerols), (lyso)phosphatidylethanolamines, and ceramides included in meta-analysis were associated with higher risk of type 2 diabetes (hazard ratio 1.07–2.58). Higher levels of glycine, glutamine, betaine, indolepropionate, and (lyso)phosphatidylcholines were associated with lower type 2 diabetes risk (hazard ratio 0.69–0.90).LIMITATIONSSubstantial heterogeneity (I2 > 50%, τ2 > 0.1) was observed for some of the metabolites.CONCLUSIONSSeveral plasma and serum metabolites, including amino acids, lipids, and carbohydrates, are associated with type 2 diabetes risk.

U2 - 10.2337/dc21-1705

DO - 10.2337/dc21-1705

M3 - Journal article

C2 - 35349649

SP - 1013

EP - 1024

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

ER -

ID: 347755451